355 related articles for article (PubMed ID: 28205126)
1. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
Saki N; Shirzad R; Rahim F; Saki Malehi A
Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
[TBL] [Abstract][Full Text] [Related]
2. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
3. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
4. Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
Abdelghani M; Hammami H; Zidi W; Amouri H; Othmen HBH; Farrah A; Menif S
J Clin Lab Anal; 2022 Aug; 36(8):e24522. PubMed ID: 35754115
[TBL] [Abstract][Full Text] [Related]
5. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
Ben Said M; Gandrille S; Fischer AM; Darnige L
Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
[TBL] [Abstract][Full Text] [Related]
7. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
8. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
[TBL] [Abstract][Full Text] [Related]
9. Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
Sun C; Zhou X; Zou ZJ; Guo HF; Li JY; Qiao C
Chin Med J (Engl); 2016 Aug; 129(15):1778-83. PubMed ID: 27453224
[TBL] [Abstract][Full Text] [Related]
10. X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations.
Allen C; Lambert JR; Linch DC; Gale RE
Blood; 2014 Sep; 124(13):2091-3. PubMed ID: 25139350
[TBL] [Abstract][Full Text] [Related]
11. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
13. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
14. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
[TBL] [Abstract][Full Text] [Related]
15. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.
Pósfai É; Marton I; Király PA; Kotosz B; Kiss-László Z; Széll M; Borbényi Z
Pathol Oncol Res; 2015 Jul; 21(3):751-8. PubMed ID: 25573593
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
18. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.
Yang Y; Wang X; Wang C; Qin Y
Int J Hematol; 2015 Feb; 101(2):165-72. PubMed ID: 25540065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
